| 纯度 | >90%SDS-PAGE. |
| 种属 | mouse |
| 靶点 | IgG2b |
| Uniprot No | P01867 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 97-335aa |
| 氨基酸序列 | EPSGPISTIN PCPPCKECHK CPAPNLEGGP SVFIFPPNIK DVLMISLTPK VTCVVVDVSE DDPDVQISWF VNNVEVHTAQ TQTHREDYNS TIRVVSTLPI QHQDWMSGKE FKCKVNNKDL PSPIERTISK IKGLVRAPQV YILPPPAEQL SRKDVSLTCL VVGFNPGDIS VEWTSNGHTE ENYKDTAPVL DSDGSYFIYS KLNMKTSKWE KTDSFSCNVR HEGLKNYYLK KTISRSPGL |
| 预测分子量 | 26 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IgG2b重组蛋白的3篇示例文献及其摘要概括(注：以下文献信息为示例，实际引用请根据真实文献调整)：
---
1. **文献名称**：Optimization of IgG2b Recombinant Protein Production in Mammalian Expression Systems
**作者**：Smith A, et al.
**摘要**：研究通过优化CHO细胞表达系统提高IgG2b重组抗体的产量，分析不同培养条件对抗体表达水平和糖基化修饰的影响，最终实现高效稳定的IgG2b生产。
2. **文献名称**：Purification and Characterization of Recombinant IgG2b for Therapeutic Applications
**作者**：Jones B, et al.
**摘要**：开发了一种基于蛋白A亲和层析和离子交换层析的两步纯化法，用于高效纯化重组IgG2b抗体，并通过质谱和功能实验验证其结构完整性和抗原结合活性。
3. **文献名称**：Structural Analysis of IgG2b Reveals Key Determinants for Fc-Mediated Effector Functions
**作者**：Lee C, et al.
**摘要**：通过定点突变和体外重组技术，解析IgG2b抗体Fc区结构与抗体依赖性细胞毒性(ADCC)及补体激活(CDC)功能的关系，为工程化改造提供依据。
---
**检索建议**：
可通过PubMed或Google Scholar搜索关键词：
`"IgG2b recombinant antibody production"`
`"IgG2b purification characterization"`
`"IgG2b structure-function analysis"`
以获取更多相关文献。
**Background of IgG2b Recombinant Proteins**
IgG2b is a subclass of immunoglobulin G (IgG), a critical component of the adaptive immune system in mammals. As one of the four IgG subclasses (IgG1. IgG2a, IgG2b, IgG3 in mice; variations exist in humans), IgG2b plays distinct roles in immune responses. It is characterized by its heavy chain structure (γ2b in mice) and exhibits unique effector functions, such as complement activation and Fc receptor binding, which influence pathogen neutralization, opsonization, and antibody-dependent cellular cytotoxicity (ADCC).
Recombinant IgG2b proteins are engineered using biotechnological approaches to produce monoclonal antibodies (mAbs) or antibody fragments with defined specificity. These proteins are generated by cloning the genes encoding the heavy (γ2b) and light chains of IgG2b into expression vectors, followed by transfection into host systems (e.g., mammalian cells like CHO or HEK293). This ensures proper post-translational modifications, including glycosylation, critical for stability and effector functions.
IgG2b recombinant antibodies are widely used in research, diagnostics, and therapeutics. In therapeutics, they target diseases like cancer, autoimmune disorders, and infections due to their balanced effector functions. For example, mouse IgG2b isotypes are often leveraged in preclinical models to study immune responses or evaluate drug efficacy. Additionally, recombinant IgG2b serves as a tool in immunoassays (e.g., ELISA, flow cytometry) for antigen detection.
Advantages of recombinant IgG2b include batch-to-batch consistency, scalability, and the ability to engineer chimeric or humanized variants to reduce immunogenicity in clinical applications. Challenges remain in optimizing expression systems and glycosylation patterns to enhance functional properties. Overall, IgG2b recombinant proteins represent a versatile platform bridging immunology and biotechnology, with expanding applications in both basic science and translational medicine.
×
